ArticleTomography (Ann Arbor, Mich.)2017
DCE-MRI Texture Features for Early Prediction of Breast Cancer Therapy Response.
Article in Tomography (Ann Arbor, Mich.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Value of Radiomics Based on DCE-MRI in distinguishing benign and malignant breast lesions: Predicting Histological Grade and Lymph Node Metastasis of Breast Cancer.Pakistan journal of medical sciences · 2026Article
- Article
- Deconvolution-Based Pharmacokinetic Analysis to Improve the Prediction of Pathological Information of Breast Cancer.Journal of imaging informatics in medicine · 2024Article
- Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting.Frontiers in oncology · 2024Article
- Review
- Textural Features of Mouse Glioma Models Measured by Dynamic Contrast-Enhanced MR Images with 3D Isotropic Resolution.Tomography (Ann Arbor, Mich.) · 2023Article
- Segmentation of cellular ultrastructures on sparsely labeled 3D electron microscopy images using deep learning.Frontiers in bioinformatics · 2023Article
- Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer.Frontiers in oncology · 2023Article
- Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study.BMC medical imaging · 2022Article
- Article
- Association between breast cancer's prognostic factors and 3D textural features of non-contrast-enhancedThe British journal of radiology · 2022Article
- Effect of Neoadjuvant Chemotherapy on Angiogenesis and Cell Proliferation of Breast Cancer Evaluated by Dynamic Enhanced Magnetic Resonance Imaging.BioMed research international · 2022Article
- Radiomics in breast MRI: current progress toward clinical application in the era of artificial intelligence.La Radiologia medica · 2022Review
- New method for quantification of intratumoral heterogeneity: a feasibility study on KMagma (New York, N.Y.) · 2021Article
- Radiomic analysis of HTR-DCE MR sequences improves diagnostic performance compared to BI-RADS analysis of breast MR lesions.European radiology · 2021Article
- A radiomics pipeline dedicated to Breast MRI: validation on a multi-scanner phantom study.Magma (New York, N.Y.) · 2021Article
- Value of Machine Learning with Multiphases CE-MRI Radiomics for Early Prediction of Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Invasive Breast Cancer.Cancer management and research · 2021Article
- The Potential Value of Texture Analysis Based on Dynamic Contrast-Enhanced MR Images in the Grading of Breast Phyllode Tumors.Frontiers in oncology · 2021Article
- Vascularity and Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging.Frontiers in radiology · 2021Review
- Quantitative ultrasound delta-radiomics during radiotherapy for monitoring treatment responses in head and neck malignancies.Future science OA · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
This study investigates the effectiveness of hundreds of texture features extracted from voxel-based dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parametric maps for early prediction of breast cancer response to neoadjuvant chemotherapy (NAC). In total, 38 patients with breast cancer underwent DCE-MRI before (baseline) and after the first of the 6-8 NAC cycles. Quantitative pharmacokinetic (PK) parameters and semiquantitative metrics were estimated from DCE-MRI time-course data. The residual cancer burden (RCB) index value was computed based on pathological analysis of surgical specimens after NAC completion. In total, 1043 texture features were extracted from each of the 13 parametric maps of quantitative PK or semiquantitative metric, and their capabilities for early prediction of RCB were examined by correlating feature changes between the 2 MRI studies with RCB. There were 1069 pairs of feature-map combinations that showed effectiveness for response prediction with 4 correlation coefficients >0.7. The 3-dimensional gray-level cooccurrence matrix was the most effective feature extraction method for therapy response prediction, and, in general, the statistical features describing texture heterogeneity were the most effective features. Quantitative PK parameters, particularly those estimated with the shutter-speed model, were more likely to generate effective features for prediction response compared with the semiquantitative metrics. The best feature-map pair could predict pathologic complete response with 100% sensitivity and 100% specificity using our cohort. In conclusion, breast tumor heterogeneity in microvasculature as measured by texture features of voxel-based DCE-MRI parametric maps could be a useful biomarker for early prediction of NAC response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.